在不响应一线治疗的抑郁症中使用米诺环素:系统性审查和元分析
Muhammad Aaqib Shamim1, Subhanwita Manna2, Pradeep Dwivedi1,3
1Department of Pharmacology, All India Institute of Medical Sciences, Jodhpur, India.
Medicine
|November 14, 2023
概括
在治疗耐药性抑郁症方面,米诺环素与安慰剂相比没有显著的益处. 需要进一步的研究,以探索其在特定患者群体和更长的治疗持续时间中的有效性.
科学领域:
- 神经科学是一个神经科学.
- 精神病学是一个精神病学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 大型抑郁症 (MDD) 影响着数以百万计的人,许多患者 (约30%) 对初始治疗没有反应,导致治疗耐药性抑郁症 (TRD).
- TRD与长时间的痛苦,增加住院和大量医疗保健费用有关.
- 抗炎药物,如米诺环素,正在对TRD进行研究,因为它们能够穿越血脑屏障并调节神经炎症,但随机对照试验 (RCT) 的结果不一致.
研究的目的:
- 系统地审查和元分析与安慰剂相比,米诺环在抑郁症患者中对至少一种一线抗抑郁药不反应的疗效.
- 评估治疗持续时间和患者神经炎症状况对治疗结果的影响.
主要方法:
- 在PubMed,Cochrane和Scopus进行了系统的文献搜索,以确定相关的随机对照试验 (RCT).
- 来自四个RCT的数据进行了元分析,以评估抑郁症严重程度,反应率和缓解率的差异.
- 使用I2统计,预测间隔和元回归来评估异质性,并相应地对证据的确定性进行评分.
主要成果:
- 对四项RCT的元分析发现,米诺环和安慰剂在降低抑郁症严重程度 (平均差异 -3.93;95% CI: -16.14至8.28),响应率 (OR 1.15;95% CI: 0.33-4.01) 或缓解率 (OR 0.94;95% CI: 0.44-2.01) 方面没有统计学上显著的差异.
- 对于抑郁症严重程度的减轻,观察到趋向于显著性 (P < 0.1).
- 抑郁症严重程度的高研究间异质性 (I2 = 78%) 由与治疗持续时间相关的元回归 (P = 0.02) 解释.
结论:
- 在治疗对一线疗法的耐药性抑郁症方面,米诺环素没有显示出与安慰剂相比的显著优势.
- 治疗结果似乎受到治疗持续时间和个体患者的神经炎症概况的影响.
- 更大,更长期的RCT,特别是在不同的患者小组中,有必要澄清米诺环林在抑郁症精准医学中的作用,并减轻与无效治疗试验相关的医疗保健成本.
相关概念视频
Antidepressant Drugs: MAOIs and Other Agents
252
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
252
Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs
410
Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...
410
Mania and Antimanic Drugs: Overview
202
Mania, a psychological condition characterized by elevated mood, increased energy, and reduced sleep need, is part of the bipolar disorder cycle. The exact cause of mania isn't entirely known, but it is thought to be a combination of genetic, environmental, and neurological factors. Bipolar disorder involves alternating manic and depressive episodes. Mood stabilizers like lithium, antipsychotics, and anticonvulsants help manage these episodes. Lithium carbonate is particularly effective as...
202
Electroconvulsive Therapy
47
Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early...
47
Antidepressant Drugs: Overview
524
Antidepressant drugs are a class of medications primarily used for treating various mood disorders, including major depression, anxiety disorders, and other related conditions. These medicines work by modulating the neurotransmitter balance within the brain, alleviating depressive symptoms. Antidepressants can be broadly categorized into several groups according to their mechanism of action and chemical structure: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine...
524
Depression: Overview
255
Depression is a prevalent mental illness marked by persistent sadness and lack of interest in previously enjoyable activities. It can take several forms, including major depression, persistent depressive disorder, and bipolar I and II disorders. Symptoms range from emotional changes like chronic worry to physical changes like sleep disturbances and suicidal thoughts. From a neurobiological perspective, depression is believed to be triggered by abnormalities in the brain's prefrontal cortex,...
255


